Pathogenesis of RA Sample Clauses

Pathogenesis of RA. The classical clinical feature of rheumatoid arthritis is synovitis. This is a term for swelling of the synovial membrane within joints. Synovitis is both initiated and maintained by a complex interplay between dendritic cells (DCs), T-Cells, B-Cells, macrophages, fibroblasts and osteoclasts15. The leukocyte infiltration of the synovial compartment is primarily due to migration of cells into the area as opposed to local proliferation. Cellular and Mollecular Pathways in RA The strong link between autoantibodies and the development of RA help to highlight the key role that the adaptive immune system plays in the pathogenesis of the disease. The synovium in rheumatoid arthritis contains many myeloid cells and plasmacytoid dendritic cells that express cytokines, HLA class II molecules, and costimulatory molecules that are necessary for T-cell activation and antigen presentation16. The efficacy of abatacept, a drug that blocks T-Cell co-stimulation, provides further evidence for the role of T-Cells in RA. T-cells against citrullinated self-peptides have been identified in individuals with RA. Type 1 (Th1) and Type 17 (Th17) t-helper cells can be activated either in the lymph nodes or in the joint by antigen presenting cells that present autoantigen peptides. These t-cells then activate macrophages and fibroblasts by the secretion of pro-inflammatory mediators including tumour necrosis factor alpha (TNFα), Interleukin 17 (IL-17), Interferon gamma (IFN-γ) and receptor activator of nuclear factor KB ligand (RANK-L)15. Activated macrophages subsequently secrete pro-inflammatory TNF-α, Interleukin 1 beta (IL- 1β), and interleukin 6 (IL-6) which promote the establishment and maintenance of an inflammatory milieu in the synovium15. Activated T cells provide help to autoreactive B cells resulting in the production of anti-ccp and RF autoantibodies. These autoantibodies drive inflammation either by direct macrophage activation or triggering the complement cascade. RANK-L produced by the activated fibroblasts promotes the differentiation of osteoclasts from macrophages15. The pathology is summarised in Figure 2 below.
AutoNDA by SimpleDocs

Related to Pathogenesis of RA

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Multiple Measures of Student Learning Measures must include a combination of classroom, school and district assessments, student growth percentiles on state assessments, if state assessments are available, and student MEPA gain scores. This definition may be revised as required by regulations or agreement of the parties upon issuance of ESE guidance expected by July 2012.

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Placement of EPP probes Probes for measuring EPP parameters shall be placed inside or close to Registrars points of access to the Internet across the different geographic regions; care shall be taken not to deploy probes behind high propagation-­‐delay links, such as satellite links.

  • Loop Provisioning Involving Integrated Digital Loop Carriers 2.6.1 Where EveryCall has requested an Unbundled Loop and BellSouth uses Integrated Digital Loop Carrier (IDLC) systems to provide the local service to the end user and BellSouth has a suitable alternate facility available, BellSouth will make such alternative facilities available to EveryCall. If a suitable alternative facility is not available, then to the extent it is technically feasible, BellSouth will implement one of the following alternative arrangements for EveryCall (e.g. hairpinning):

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

Time is Money Join Law Insider Premium to draft better contracts faster.